AstraZeneca will supply 200 doses of the coronavirus vaccine candidate AZD1222 to the U.S. Army under a $286.9M firm-fixed-price contract.
The military branch received one bid for the procurement effort and obligated the full value of the award, the Department of Defense said Thursday.
Contract work will take place in Albuquerque, New Mexico, and West Chester Township, Ohio, through June 30, 2021.
The University of Oxford in England co-invented AZD1222 with Vaccitech, a biotechnology company that was spun out of the university's Jenner Institute.
AstraZeneca said Oct. 23 it resumed late-stage clinical trials of the experimental vaccine in the U.S.after the Food and Drug Administration completed a review of drug safety data.
